Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

PlasmaTech Biopharmaceuticals Inc. (PTBI)

Add PTBI Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator jbem777
Search This Board:
Last Post: 4/26/2015 2:20:35 PM - Followers: 33 - Board type: Free - Posts Today: 0


 Company Overview

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that focuses on adding value to exciting product concepts in research by advancing those products through clinical development. Access has adopted a semi-virtual model to control costs, and advances projects by utilizing its experienced clinical and regulatory team and a small team of experienced pharmaceutical scientists. Access's scientists have unique expertise in nanopolymer chemistry platform technologies, which are utilized in several of the company's R&D programs. Through careful strategic planning designed to maximize shareholder returns, Access will either seek to advance products towards regulatory and marketing approval, co-develop products in collaboration with R&D and marketing partners or out-license products once development has advanced to a predetermined point.

While the the company's primary focus is in oncology and supportive care of cancer patients, Access has recently acquired product candidates in the dermatology field as well as additional oncology assets. Access has an approved supportive care product, one product in Phase 3 clinical development, four Phase 2 clinical candidates, and six preclinical programs in oncology, including products arising from a promising oral drug delivery technology.

In the area of supportive care, Access has received marketing allowance for MuGard in the United States from the Food and Drug Administration (FDA). MuGard is indicated for management of mucositis. Mucositis is a debilitating side effect of various cancer treatments resulting in ulceration of the oral cavity. MuGard, a proprietary nanopolymer rinse formulation, provides a protective coating to the mucosal surfaces in the mouth. A clinical study has shown MuGard to be effective in lowering the incidence and severity of mucositis. The market for mucositis treatment is estimated to be in excess of US$1 billion world-wide. In addition to receiving FDA marketing allowance in the U.S., Access has marketing partners for MuGard in three major world territories; SpePharm, for the commercialization of MuGard in the EU, Milestone Biosciences for North America, and RHEI Pharmaceuticals for certain Asian territories

ProLindac links Access' nanopolymer technolgy with the principals of prodrugs to enhance the delivery of a platinum drug to tumors. In preclinical models ProLindac protects normal tissue from the cytotoxic drug while in circulation and enhances uptake of drugs to tumors, where drug is released by virtue of a pH-sensitive linker. ProLindac completed a Phase 1 clinical study demonstrating promising signs of efficacy. ProLindac has completed a Phase 2 clinical study in patients with recurrent ovarian cancer. The drug used in ProLindac is DACH platinum, which is also the active moiety of oxaliplatin (Eloxatin; Sanofi  Aventis), a drug which currently has sales of over $2.0 billion worldwide. Access has a codevelopment agreement with Nanjing Aosaikang Medicinal Group for development of ProLindac in China.

Thiarabine is a novel nucleoside product which demonstrated very promising anticancer activity in preclinical models. Following completion of two Phase 1 clinical studies, Access plans to advance thiarabine in a Phase 2 study at a leading US institute for the treatment of leukemia.

Access also has Cobalamin technologies in early-stage development. This technology is based upon the use of cobalamin coated particles derived from the company's nanopolymer chemistry technlogies. The company has extensive intellectual property surrounding the use of this technology for oral drug delivery including oral delivery of insulin and other proteins and peptides. Access receives funding from a major pharmaceutical company for the development of a Cobalamin oral drug delivery formulation of human growth hormone. In preclinical development are the Angiolix®, Prodrax®, Alchemix®, and Cobalamin programs, which have the potential to provide an exciting array of new clinical candidates.

Angiolix (HuMc3) is a humanized monoclonal antibody which binds to Lactadherin, a 46kDa extracellular matrix protein, expressed by most breast tumor cells. This binding blocks vascular endothelial cell proliferation, and induces selective programmed cell death (apoptosis) in blood vessels supporting tumors. This cuts off or reduces the supply of nutrients and oxygen to tumors and reduces tumor growth. Angiolix thus acts as an anti-angiogenesis factor like drugs such as Avastin. In preclinical studies, Angiolix displays potent anti-tumor activity in the MX-1 breast cancer tumor model.

Prodrax is a non-toxic prodrug which is targeted to be active in the low oxygen (hypoxic) regions of solid tumors. The Prodrax program comprises a series of compounds which are N-oxide prodrugs of cytotoxic anthraquinone derivatives. The N-oxide deactivates the toxic cytotoxic alkylating function while the drug is in circulation; it also serves to enhance the ability of the compound to traverse biological membranes, ensuring that the prodrug is widely distributed in the body. Prodrax compounds are non-toxic in normally oxygenated tissues as well as the oxygenated areas of solid tumors but become highly toxic in the low oxygen (hypoxic) region of tumors.

Alchemix molecules are proprietary molecules that attack tumors by two modes of action: through intercalating and alkylating properties that result in irreversible binding of the compounds to tumor DNA, thus preventing tumor replication and inducing tumor cell death. It has also been shown that Alchemix molecules are a potent inhibitors of topoisomerase II. Alchemix molecules possess potent activity across a variety of different human tumor cell lines and significantly show potent activity in cisplatin and anthracyline resistant xenograft human tumor models.

The Cobalamin oral drug delivery technology has been extended to provide nanoparticulate formulations for the enhanced targeting of drugs to sites of disease. Targeting results from the increased demand for vitamins such as cobalamin that often occurs at disease sites, such as cancer.

Access is developing Phenylbutyrate (PB) which is also in Phase 2 clinical trials. PB is a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. HDAC inhibitors have potent anticancer activity by suppressing specific enzymes found in cancer cells.

Access recently acquired two dermatological products as well as the proprietary nanopolymer drug delivery technology used in one of these products. Pexiganan is topical product for the treatment of diabetic foot ulcers. It is based on the proprietary synthetic analog of a naturally-occuring broad-spectrum antimicrobial peptide. Clinical studies have shown Pexiganan to be at least as effective as one of the standard oral antibiotics used in the treatment of diabetic foot ulcers, without the potential issues of systemic use of antibiotic. EcoNail is a nail lacquer for the treatment of onychomycosis, a common nail fungal infection.

Access Pharmaceuticals Inc.
2600 Stemmons Freeway
Suite 176
Dallas, TX 75207
United States - Map
Phone: 214-905-5100
Fax: 214-905-5101
Web Site:

Product Pipeline


Shares Outstanding5: 13.11M
Float: 8.82M
% Held by Insiders1: 35.59%
% Held by Institutions1: 1.30%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for PTBI
PTBI News: Current Report Filing (8-k) 04/24/2015 04:29:05 PM
PTBI News: Current Report Filing (8-k) 04/07/2015 05:15:52 PM
PTBI News: Proxy Statement (definitive) (def 14a) 04/07/2015 04:38:24 PM
PTBI News: PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board 04/07/2015 09:05:00 AM
PTBI News: PlasmaTech Biopharmaceuticals' Announces $5 million private placement 04/02/2015 09:05:00 AM
#99  Sticky Note PTBI DD-Information for New Investors jbem777 04/21/15 12:48:51 PM
#187   Think you are right Bob, anyone able to salgovernale69 04/26/15 02:20:35 PM
#186   Always awesome to have you aboard bob. This moneypennyoncs 04/26/15 10:29:14 AM
#185   That is what grabbed me. Revenues from MuGard tpizzazz24 04/25/15 10:04:34 PM
#184   With approval of SDF ... It will hit Bob Stocks 04/25/15 09:47:09 PM
#183   Honestly, I think it hits 10...I will probably Bob Stocks 04/25/15 09:45:04 PM
#182   100% puts it at 7+ I can see this tpizzazz24 04/25/15 09:44:04 PM
#181   Some are speculating a return to $20-30. scottsmith 04/25/15 09:43:24 PM
#180   I will hold for awhile unless it pops 100% Bob Stocks 04/25/15 09:37:52 PM
#179   Thanks Bob We need to get the rest of tpizzazz24 04/25/15 09:36:28 PM
#178   I will post there this week...PTBI very undervalued...Jbem Bob Stocks 04/25/15 09:24:01 PM
#177   It is a good community. I belive there is tpizzazz24 04/25/15 08:10:05 PM
#176   Thanks for starting that tpizazz. I'm not salgovernale69 04/25/15 08:06:30 PM
#175   Forgive my error about this week's low .21 I tpizzazz24 04/25/15 06:58:01 PM
#174   Hello everyone. PTBI had an amazing week. Congratulations tpizzazz24 04/25/15 06:30:23 PM
#173   Check out the sticky. scottsmith 04/25/15 01:06:44 PM
#172   Great find. Like to look into this more. Are there tpizzazz24 04/25/15 12:56:41 PM
#171   Thanks for finding that salgovernale69. moneypennyoncs 04/25/15 09:58:40 AM
#170   tpizz, you may have seen this but below salgovernale69 04/25/15 07:17:15 AM
#169   Do you have any idea what the royalties tpizzazz24 04/24/15 07:21:57 PM
#168   Bought some yesterday and today. Canoepaddler 04/24/15 07:12:16 PM
#167   Does anyone know what the royalties are for tpizzazz24 04/24/15 04:30:47 PM
#166   Thank you. jembers 04/24/15 01:34:24 PM
#165   Two dilutions, reverse split and lack of news. moneypennyoncs 04/24/15 01:33:34 PM
#164   Any clue as to the fall from $30 jembers 04/24/15 01:22:12 PM
#163   Lol. Yup. moneypennyoncs 04/24/15 01:16:30 PM
#162   Yeah, I take it all back, I'm fine jembers 04/24/15 01:16:03 PM
#161   I'm going on record to say that I'm moneypennyoncs 04/24/15 01:07:05 PM
#160   Lol! I'll be happy with 100%. He can jbem777 04/24/15 12:58:26 PM
#159   lol... true. I just want it soaring in jembers 04/24/15 12:35:13 PM
#158   Honestly, do we want anything than the pps soaring? moneypennyoncs 04/24/15 12:28:56 PM
#157   The only thing I don't like seeing, although jembers 04/24/15 12:22:48 PM
#156   Very nice. This is brewing right now. About moneypennyoncs 04/24/15 12:17:28 PM
#155   Took a position here today after seeing a jembers 04/24/15 12:04:18 PM
#154   Load up folks, this is about to take jbem777 04/24/15 11:46:39 AM
#153   Yep, caught your rec on the SYN YMB. I tpizzazz24 04/23/15 06:12:42 PM
#152   Congrats on getting in tpizz. Great volume salgovernale69 04/23/15 05:38:52 PM
#151   Got in this morning. Was up all night tpizzazz24 04/23/15 01:38:24 PM
#150   Thanks for pointing me in the right directions. scottsmith 04/23/15 12:46:46 PM
#149   Excellent timing. jbem777 04/23/15 12:40:22 PM
#148   You sure did scottsmith. Jbeam777 is solid. I've moneypennyoncs 04/23/15 12:27:25 PM
#147   Looks like I got in just in time. scottsmith 04/23/15 12:25:43 PM
#146   Here we go. moneypennyoncs 04/23/15 12:07:42 PM
#145   You all convinced me; I'm in. Seems scottsmith 04/23/15 11:35:22 AM
#144   Looking good here. If you are not in moneypennyoncs 04/23/15 11:12:04 AM
#143   Another stock I'm in -- CTIX -- is scottsmith 04/23/15 10:30:48 AM
#142   Because of the low float, the spread can jbem777 04/23/15 10:05:24 AM
#141   I just bought more. The potential here is astounding. moneypennyoncs 04/23/15 09:46:46 AM
#140   Just jumped back to 3.35. Don't know scottsmith 04/23/15 09:45:50 AM
#139   I'm seeing PTBI down to 3.14 but the scottsmith 04/23/15 09:33:57 AM
#138   PTBI- New article out today. Shows just how jbem777 04/23/15 09:26:49 AM